pancreatic cancer
Conditions
Interventions
On-line adaptive intensity-modulated radiotherapy to the tumor and draining lymph node at risk
(Borderline resectable pancreatic cancer) 42 Gy/15 fr
(Locally advanced pancreatic cancer) 48 Gy/15 fr
Gemcitabine
administered by intravenous drip infusion every week at a dose of 1000 mg/m2 for 3 weeks.
Sponsors
Mizowaki Takashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Confirmed pancreatic adenocarcinoma or adenosquamous cell carcinoma by endoscopic ultrasound-fine needle aspiration. Or cytology of class IV or V and imaging findings consistent with adenocarcinoma or adenosquamous cell carcinoma. 2. Patients with borderline resectable pancreatic cancer or locally advance pancreatic cancer. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion criteria
Exclusion criteria: 1. Patients who have received radiotherapy to upper abdomen. 2. Tumor with direct invasion to stomach, duodenum, or small intestine. 3. Patients who cannot be treated expiratory breath-hold technique.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute Grade 3 or higher adverse event non-incident rate which gastrointestinal origin | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion probability of treatment protocol, Adverse event rate except for gastrointestinal origin, Treatment time, Intra-fractional motion of organ, Inter-fractional motion of organ, Dosimetric parameters in adaptive and non-adaptive plan, The contour difference between in treatment and after treatment, The contour difference between operators, The optimal margin of organ at risk in oART | — |
Contacts
Public ContactTakahiro Iwai
Kyoto University Hospital
Outcome results
None listed